Converting biology into digital molecular maps
Finding new cures requires seeing what and where the abnormal molecules are in a diseased tissue, but current tools see less than 1% of those molecules. Biocartesian combines microscopy and new chemistries to see 50X more, offering unprecedented insights into disease biology and new therapies.
What they do:
We make injections as easy as pushing a button!
Quick facts:
HQ: Boston, MA, United States
What they do:
Redefining the Standard of Care for Iron Deficiency Anemia
Quick facts:
HQ: San Francisco, CA, United States
What they do:
Artificial intelligence for drug discovery.
Quick facts:
HQ: San Francisco, CA, United States
Funding:
$19.8M · Equity · Mar 2026
What they do:
Engineering a future without cancer deaths.
Quick facts:
HQ: San Francisco, CA, United States
What they do:
Arpeggio Bio develops drugs targeting transcription factors using AI…
Quick facts:
HQ: Boulder, CO, United States
What they do:
The next generation of induced-proximity medicines.
Quick facts:
HQ: San Francisco, CA, United States
Converting biology into digital molecular maps
Philadelphia, PA, United States
2 employees, according to the company profile.
There are no funding rounds for Biocartesian in our data.
Similar startups: Pirouette Pharma, Keylika, and Numerion Labs.